Skip to main content

Table 1 Characteristics of Massachusetts commercially insured patients with buprenorphine prescriptions and by treatment discontinuationa status

From: A machine learning based two-stage clinical decision support system for predicting patients’ discontinuation from opioid use disorder treatment: retrospective observational study

 

Total

Continued

Discontinued

RR (95% CI)

P value

Number of patients

5190

2665

2525

  

Patient characteristics

Patient age

36.4 ± 11.3

37.3 ± 10.9

35.6 ± 11.5

N/A

 < 0.001

Patient income

72,109 ± 13,087

71,581 ± 12,961

72,667 ± 13,199

N/A

0.003

Patient gender

     

 Male

3165 (61)

1596 (59.9)

1569 (62.1)

0.95(0.89, 1.01)

0.09

 Female

2025 (39)

1069 (40.1)

956 (37.9)

Reference

Reference

Patient location

 Urban

3582 (69)

1793 (67.3)

1789 (70.9)

Reference

Reference

 Rural

1608 (31)

872 (32.7)

736 (29.1)

0.92 (0.86, 0.97)

0.005

Insurance type

 HMO

1212 (23.4)

521 (19.5)

691 (27.4)

1.27 (1.19, 1.35)

 < 0.001

 PPO

427 (8.2)

187 (7)

240 (9.5)

1.25 (1.14, 1.37)

 < 0.001

 Others

3551 (68.4)

1957 (73.5)

1594 (63.1)

Reference

Reference

Provider specialty

 Primary care

2951 (56.9)

1537 (57.7)

1414 (56)

0.93 (0.87, 0.99)

0.06

 Psychiatry

1055 (20.3)

553 (20.8)

502 (19.9)

0.92 (0.85, 1.01)

0.04

 Others

1184 (22.8)

575 (21.5)

609 (24.1)

Reference

Reference

Addiction treatment specialist

 No

4831 (84.4)

2481 (93.1)

2350 (93.1)

Reference

Reference

 Yes

359 (15.6)

184 (6.9)

175 (6.9)

1.00 (0.90, 1.12)

0.97

Pain specialist

 No

5114 (98.5)

2633 (98.8)

2481 (98.3)

Reference

Reference

 Yes

76 (1.5)

32 (1.2)

44 (1.7)

1.19 (0.98, 1.44)

0.11

Patients’ early treatment adherence

Patients’ PDC within first two months (continuous measure)

88.0 ± 25.6

95.3 ± 16.7

80.3 ± 30.6

N/A

 < 0.001

Patients’ PDC within first three months (continuous measure)

84.3 ± 28.9

94.2 ± 19.0

73.9 ± 33.6

N/A

 < 0.001

PDC within first two months

 High (\(\ge\) 80%)

4209 (81.1)

2459 (92.3)

1750 (69.3)

Reference

Reference

 Low (\(<\) 80%)

981 (18.9)

206 (7.7)

775 (30.7)

1.90 (1.81, 1.99)

 < 0.001

PDC within first three months

 High (\(\ge\) 80%)

3924 (75.6)

2424 (91)

1500 (59.4)

Reference

Reference

 Low (\(<\) 80%)

1266 (24.4)

241 (9)

1025 (40.6)

2.11 (2.01, 2.22)

 < 0.001

  1. aTreatment discontinuation was defined as a gap of 60 consecutive days without a buprenorphine prescription
  2. Differences were calculated for the patient-level characteristics with continuous measures using p-values computed from a t-test
Back to article page

BMC Medical Informatics and Decision Making

ISSN: 1472-6947

Contact us